Understanding the heterogeneous genetic mechanisms of tumor initiation in lymphoid leukemias (LL) will lead to improvements in prognostic classification and treatment regimens. In previous studies of mouse leukemias, we showed that retroviral insertion at the ecotropic viral insertion site 32 locus leads to increased expression of Prdm14, a pluripotency gene implicated in the selfrenewal capacity of embryonic stem cells and the early stages of breast cancer. Here, we show that PRDM14 is also overexpressed in B25% of human lymphoid neoplasms, with increased frequencies in T-cell acute LL and hyperdiploid precursor B-cell acute LL. To test if Prdm14 overexpression could initiate leukemia, mice were transduced with bone marrow cells transfected with a Prdm14 expression vector. LLs developed in 96% of female mice and 42% of male mice. Before the onset of leukemia, differentiation of transduced cells was biased up to 1000fold toward cells with features of common lymphoid progenitors (CLPs), and lymphoid differentiation showed a relative block at the pro-B stage. Microarray gene expression analysis of expanded CLP-like cells before the onset of leukemia demonstrated upregulation of genes involved in pluripotency, tumor initiation, early B-lineage commitment, Wnt/Ras signaling and the epithelial-tomesenchymal transition. Among the dysregulated genes were imprinted genes and non-coding RNAs including Dlk1 and Meg3, which are also key pluripotency mediators. Heightened expression of the estrogen-dependent oncogene, Myb, in tumors suggests a basis for the increased frequency of cancer in female mice. These data provide the first direct evidence for the association of Prdm14 with cancer initiation in an in vivo mouse model and in human lymphoid malignancies, while suggesting mechanisms for Prdm14's mode of action.
Introduction
Acute lymphoblastic leukemias (ALLs), neoplasms of lymphoid precursors of the T-and B-cell lineages, are variably curable based on age of presentation, disease burden at diagnosis, immunophenotype and cytogenetic abnormalities (Pizzo and Poplack, 2006) . Genomic aberrations detected by standard karyotypic analyses involve large chromosomal rearrangements (such as translocations), aneuploidy, and the gain or loss of large chromosomal regions. The advent of high-throughput genomic technologies changed our view of leukemias, however, by showing that large numbers of more subtle genetic abnormalities are present in tumor cells. Key genes, such as PAX5 and IKZF1, important for normal lymphoid lineage commitment, are altered in ALL, often by copy number variations, such as deletion or amplification rather than translocation (Mullighan et al., 2005 (Mullighan et al., , 2007 (Mullighan et al., , 2008 (Mullighan et al., , 2009 Downing and Mullighan, 2006) . Nevertheless, genetic aberrations that trigger the initiation of lymphoid leukemias and lymphomas other than the balanced translocations involving immunoglobulin and T-cell receptor genes remain largely unknown.
In mice, retroviral insertion is a powerful strategy to identify genes implicated in the initiation of leukemia (Jonkers and Berns 1996; Hansen et al., 2000; Suzuki et al., 2002; Akagi et al., 2004) . In certain inbred strains, the somatic insertion of retroviruses may activate expression of nearby proto-oncogenes or disrupt tumor-suppressor genes. In these mouse tumors, common proviral insertion sites identify loci involved in the onset and progression of hematologic malignancies. We previously showed that mouse lymphoid malignancies containing retroviral insertions at the common proviral insertion site designated ecotropic viral insertion site 32 had very high expression of the PRDI-BF1 RIZ homology domain (PR) domain gene Prdm14, implicating this gene in the pathogenesis of mouse lymphoblastic leukemia (LL) for the first time (Weiser et al., 2007; Dettman and Justice, 2008) .
Prdm14 (human ortholog PRDM14) is a member of the PR domain-containing family of transcription factors, which are crucial for normal hematopoiesis and can behave as tumor suppressors or as protooncogenes (Jiang and Huang, 2000; Fumasoni et al., 2007; Kinameri et al., 2008) . Although the molecular function of PRDM14 is largely unknown, sequence homology analyses suggest it may have histone methyltransferase activity, similar to other PRDM family members Hayashi et al., 2005; Baudat et al., 2010; Myers et al., 2010; Parvanov et al., 2010) . PRDM14 contains an N-terminal PR domain followed by six DNA-binding C2H2 zinc fingers (Fumasoni et al., 2007) . The PR domain is similar to the Su(var)3-9, enhancer of zeste [E(z)], and trithorax domain, which has global histone methyltransferase activity.
Expression of Prdm14 is normally restricted to pluripotent cells. In embryonic stem cells, PRDM14 suppresses the expression of molecular markers associated with differentiation (Tsuneyoshi et al., 2008) . PRDM14 mediates pluripotency in human embryonic stem cells by directly binding the proximal enhancer of the key pluripotency gene POU5F1 (OCT3/4) (Chia et al., 2010) . Prdm14 is also expressed in primordial germ cells (PGCs) of mouse embryos from embryonic day (E) 6.5 until E 14.5, when it is required to establish the pluripotency of nascent PGCs by epigenetic reprogramming. As a result, mice with a null mutation of Prdm14 fail to develop germ cells and are infertile Yamaji et al., 2008) .
In addition to its normal role in resetting pluripotency, PRDM14 has oncogenic activity with overexpression correlating with early stages of breast cancer. Importantly, expression of PRDM14 reduced the chemosensitivity of cultured cancer cells and enhanced their proliferation, while small interfering RNAmediated knockdown of gene expression augmented their chemosensitivity (Nishikawa et al., 2007) . Furthermore, the 8q13.3 region containing PRDM14 is amplified in 34-75% of human breast cancers (Nishikawa et al., 2007; Moelans et al., 2010) .
Given the oncogenic potential of this pluripotency gene in mouse and human malignancy, we investigated the possible contribution of Prdm14 as an oncogene in mouse bone marrow (BM)-derived hematopoietic cells. Before leukemic transformation, overexpression of Prdm14 caused a dramatic developmental shift characterized by expansion of pre-leukemic cells that share an immunophenotype with common lymphoid progenitors (CLPs). Pre-leukemic and leukemic cells with dysregulated Prdm14 overexpressed markers of stem cells and activators of oncogenic pathways. Thus, Prdm14 may initiate leukemia in a manner consistent with its role in the epigenetic regulation of pluripotency.
Results

Expression of Prdm14 in mouse hematopoietic cells
The coding sequence of Prdm14 was subcloned into the murine stem cell virus internal ribosomal entry site green fluorescent protein R1 (MIGR1) retroviral vector ( Figure 1a ) followed by an internal ribosome entry site for co-translation of green fluorescent protein (GFP) to permit tracking of transduced cells. The same MIGR1 empty vector (EV) without Prdm14 was used as a control. BM cells from 5-fluorouracil-treated CD45.2 mice were infected with each retrovirus (Figure 1b ). Lethally irradiated CD45.1 mice were reconstituted with the transduced cells, allowing for the identification of donor cells with antibodies specific for CD45.2 and transduced cells by GFP fluorescence. Northern blot analyses identified GFP and Prdm14 transcripts of expected sizes, although GFP transcripts expressed from the Prdm14-MIGR1 vector were present at lower levels than those from the control vector in cells transduced with equivalent multiplicities of infection ( Figure 1c ). Successful engraftment of CD45.2 þ donor cells was observed at 4 weeks after reconstitution ( Figure 1d ). However, the frequency and fluorescence intensity of GFP þ cells in the peripheral blood (PB) of Prdm14-MIGR1 recipients were lower than for EV-MIGR1 recipients ( Figure 1d ).
Overexpression of Prdm14 causes skewing of lymphoid progenitor cell populations
Recipients of Prdm14-MIGR1 or EV-MIGR1-transduced BM cells were examined at 4, 8 and 12 weeks after transfer to evaluate effects on hematopoiesis. Studies of recipient BM cells obtained at 4 weeks after reconstitution showed that although the frequencies of GFP þ cells were generally comparable for recipients of either transfected population (Figure 2a , left panels), they differed drastically in immunophenotype. The BM of normal mice contains a small population of cells (B0.02% of total BM cells) termed CLPs (Kondo et al., 1997) that do not express lineage-specific markers of mature hematopoietic cells (lin À ) but express the interleukin (IL)-7 receptor alpha chain (IL-7Ra), the Kit receptor tyrosine kinase (c-Kit, CD117) and Sca1 (Ly6a). The BM of Prdm14 recipients had a population of early lymphoid progenitor (IL-7Ra þ lin À ) cells that was over 30-fold greater than in EV recipients (Figure 2a ). IL-7Ra þ lin À cells expressing both Kit and Sca1 at high levels were also 15-fold more frequent in Prdm14 recipients (Figure 2a ), with the great majority of cells being clearly Kit þ while expressing Sca1 at intermediate levels. Data from multiple mice indicate that the BM of Prdm14 recipients had a dramatically expanded population of these early lymphoid and CLPlike cells 4 weeks after reconstitution, ranging from 3 to 12% of the transduced BM population, a frequency 250-1000-fold greater than in EV recipients ( Figure 2b ). This expansion was specific to the GFP þ Prdm14expressing subset of cells in these mice; both the GFP À population and BM from EV recipients contained only rare early lymphocyte progenitors and CLPs (Supplementary Figure 1 ).
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Prdm14 GFP GAPDH 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 (Figure 2c,d) , although the magnitude of difference for the IL-7Ra þ lin À population compared with that for EV recipients was still quite high at 26.5-fold. At this time point, 25% of GFP þ cells in PRDM14 recipient BM were lin þ , in keeping with significant increases in both the BM and PB of cells expressing B220, a marker expressed by B lineage cells from the pre-pro-B to mature B-cell stages of differentiation. The proportions of B220 þ cells were significantly lower in Prdm14 recipients at 4 and 8 weeks after reconstitution, but were higher in BM at 12 weeks (Figure 2e ). The proportions of B220 þ cells in PB were significantly higher for Prdm14 recipients at all time points examined (Figure 2e ). We then determined if the altered B220 þ BM populations were comparable for all stages of B-cell differentiation in the BM. Fluorescence-activated cell sorting analyses of B-cell subsets at 4 weeks after reconstitution with Prdm14-or EV-transfected cells revealed no significant differences in the cell populations at any stage of differentiation ( Figure 2f ). At 12 weeks, however, the populations of pre-pro-B, pre-B and immature B cells were significantly reduced, and the proportions of pro-B cells were significantly increased in BM of Prdm14 recipients compared with EV recipients (Figure 2f ). These findings indicated that the dominant CLP-like population, present at 4 weeks in the BM of Prdm14 recipients, had undergone differentiation within the B-cell lineage by 12 weeks after reconstitution, but that there was a relative block in maturation at the pro-B to pre-B transition. Consistent with the findings of a biased maturation within the B-cell lineage, transduced cells from Prdm14 recipients exhibited reduced myeloerythroid developmental potential ( Supplementary  Figures 2a-c ). Furthermore, Prdm14-transduced cells were less likely to contribute to thymic and peripheral T cells ( Supplementary Figures 2d and e ).
Mice transduced with Prdm14 develop LL A total of 103 Prdm14 recipient mice and 74 EV recipient mice were followed for up to 1 year after reconstitution. Beginning as early as 100 days after BM transplantation, Prdm14 recipients developed labored breathing, lethargy, cachexia, hind limb paralysis and kyphosis, ultimately progressing to death. By 52 weeks, 80% of the Prdm14 recipients had been euthanized when moribund or had died compared with only 12% of EV recipients. Notably, 96% (69/72) of female recipients had died by 1 year after reconstitution compared with only 42% (13/31) of male recipients (Figure 3a ). At necropsy, almost all moribund Prdm14 recipients had splenomegaly, with lower frequencies exhibiting lymphadenopathy, hepatomegaly, enlarged thymi and PB lymphoblasts ( Figure 3b ).
Analysis of slides stained with hematoxylin and eosin prepared from tissues obtained at necropsy showed that all moribund Prdm14 recipients died with LL involving the spleen and lymph nodes and often associated with involvement of the thymus and BM (Figure 3d ). Diagnoses of overt leukemia were based on the presence of lymphoblasts in hepatic blood vessels as well as blasts seen in PB. Hyperactivity of splenic red pulp elements was evidenced by expanded populations of megakaryocytes in about 17% of cases (data not shown) but without established features of megakaryocytic leukemia (Hao et al., 2006) . Erythroblastosis was found in a small number of other cases. In contrast, moribund EV recipients had no evidence of LL or proliferative expansions of other lineages.
Clonality of the LL was confirmed by the detection of clonal proviral insertions and immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements by Southern analysis. In addition, quantitative PCR analyses showed that the tumors overexpressed Prdm14 (Figure 3c ). Furthermore, syngeneic mice injected intraperitoneally with tumor cells from Prdm14 recipients rapidly succumbed to leukemias that were clonally identical to the parental tumors ( Supplementary Figure 3a) .
The histopathologic diagnosis of LL is consistent with the origins of tumors from thymic T cells, BM-derived precursor B cells, or more mature peripheral B cells . To discriminate among these possibilities, DNA prepared from the tumors was examined by Southern blotting for the organization of Ig heavy chain (IgH) and Ig kappa light chain (IgK) gene segments. The results of these studies showed that 65% of evaluated malignancies had clonal rearrangements at the IgH locus, but none had IgK rearrangements ( Supplementary Figure 3b and data not shown). This indicated that the tumors with clonal IgH rearrangements were arrested at the pro-B-cell stage of (e) BM and PB cells underwent flow cytometry for B220 þ elements of the B-cell lineage at 4, 8 and 12 weeks. GFP þ PB cells from Prdm14 recipients were skewed toward the B-cell lineage at all time points compared with cells from EV recipients. GFP þ BM cells were not committed to the B-cell lineage at 4 weeks compared to EV BM cells but later appear to skew toward the B-cell lineage (but not significantly) at 12 weeks after transplantation. (f) Flow cytometry was carried out on BM cells from transduced mice at successive time points after transplantation using early B-cell lineage markers (B220, CD43, CD19 and IgM). At 12 weeks after transplantation, cells accumulate at the pro-B stage, but differentiation past this point is markedly differentiation, which is characterized by V(D)J rearrangements at IgH with the IgK locus in germline configuration. Studies of the same DNAs revealed that 12% of the cases had clonal rearrangements at the TCR Jb1 or Jb2 loci, indicating a T-cell origin (Supplementary Figure 3c and data not shown). Co-existing clonal rearrangements of IgH and TCR loci were identified in 19% of cases, indicating the presence of composite tumors comprising distinct neoplasms of T-and B-cell origin, B lineage tumors that have undergone nonproductive rearrangements at TCR loci, or T lineage tumors with DJ only rearrangements in IgH. Of note, one tumor had no Ig or TCR rearrangement but was classified as LL by histopathology. Prdm14 CD8 SSC GFP 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 10 0 10 1 10 2 10 3 GFP CD4 10 0 10 1 10 2 10 3 CD4
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91.05 Flow cytometric studies showed that the LL expressed cell surface markers characteristic of lymphoid progenitors, B cells, or T cells, consistent with lineage assignments inferred from clonal rearrangements of Ig and TCR loci. The percentages of GFP þ tumor cells in BM, thymus, blood and peripheral lymphoid tissues ranged from B40 to 495% of all white blood cells (Figures 4a-c and data not shown). Most tumors analyzed were B220 þ , indicative of origins from B lineage cells. More detailed analyses indicated that the B220 þ tumors were arrested at different stages of early B-cell development including CD19 À CD43 þ IgM À pre-pro-B cells as well as CD19 þ CD43 þ IgM À pro-B cells (Figure 4a ). BM and thymi from mice that developed T-lineage tumors were populated by CD4 þ CD8 þ cells similar to the 'doublepositive' population found in normal thymus but not in spleen (Figure 4b) . Notably, all LL with thymic involvement carried clonal TCR rearrangements, and were classified as either pre-T-cell or mixed tumors by molecular rearrangements. One LL examined by flow cytometry was lin À but expressed IL-7Ra and Kit at high levels and Sca1 at intermediate levels (Figure 4c ), a phenotype like that of normal CLPs (Kondo et al., 1997) .
Expanded CLP-like cells and tumors in Prdm14transduced mice express genes associated with pluripotency, early B-cell development, and oncogenesis In order to determine downstream effects of Prdm14 expression, populations of CLP-like cells (IL-7Ra þ lin À Kit þ Sca1 þ ) were isolated from Prdm14-transduced and EV-transduced mice at 4 weeks post transplantation, and examined for transcript profiles using microarrays. A total of 1450 genes were differentially expressed (Pp0.05) between the two groups. Of genes with fold change differences of 1.5 and higher, 284 were upregulated and 125 were downregulated in CLP-like cells from Prdm14-transduced mice (Supplementary Table 1 ). Correlation of differential expression distinguished between Prdm14-transduced and EVtransduced IL-7Ra þ lin À Kit þ Sca1 þ cells (Supplementary Figure 4 ). Gene ontology and pathway analyses of differentially expressed genes revealed genes involved in early B-cell lineage commitment; regulators and mediators of Wnt, AKT and Ras pathways; epithelial-tomesenchymal transition (EMT); and previously wellcharacterized oncogenes (Figure 5a ). Strikingly, a number of the transcripts distinguishing the two cell populations examined were for genes or non-coding RNAs that are regulated by imprinting. Both maternally and paternally imprinted genes were overexpressed, including genes expressed from the same locus such as Dlk1 and Meg3 (Gtl2). Downregulated genes included signal transduction kinases and B-cell activation genes (Figure 5a ). Data from gene expression profiles of selected genes in individual splenic tumors from Prdm14-transduced mice showed sustained upregulation of imprinted genes such as Meg3 and Dlk1. Strikingly, additional genes were upregulated in tumors, including the pluripotency gene Pou5f1 and Prdm14 0 s PGC partner Prdm1 (Figure 5b) . Myb was highly expressed in Prdm14-induced LLs, but not in pre-leukemic cells (Figure 5b) . Myb protein was also upregulated in tumors compared with pre-leukemic cells overexpressing Prdm14 (Figure 5c ). Sox2 was downregulated, but other pluripotency genes (Nanog) and early B-cell genes (Pax5, Ebf1 and Pu.1) were expressed at similar levels in tumors compared with controls (Figure 5b, Supplementary Figure 5 ).
PRDM14 is overexpressed in a subset of human ALLs We next determined the degree and frequency and levels of PRDM14 expression in human ALL. Outlier analyses of microarray gene expression data from multiple previous studies of pediatric ALL showed that the levels of PRDM14 expression in a subset of 10-25% of patients placed PRDM14 among the top 1-2% of most overexpressed of all genes in these cohorts (Ross et al., 2003; Bhojwani et al., 2006; Maser et al., 2007; Sorich et al., 2008) . In one study of 132 patients, in which cytogenetic abnormalities and histology were available, overexpression of PRDM14 was associated most frequently with high hyperdiploid (chromosome number 450) tumors as well as T-cell acute LL (T-ALL) ( Figure 6a ) (Ross et al., 2003) .
In light of these findings, we examined PRDM14 expression levels in primary tumor samples from patients with high hyperdiploid ALL and T-ALL. Preliminary analysis of 24 samples confirmed PRDM14 expression in 9/12 (75%) of high hyperdiploid precursor B-cell acute LLs and 7/12 (58%) of T-ALL samples (Figure 6b ). Although the levels of PRDM14 expression were low relative to expression levels of reference genes (data not shown), the transcript levels in PRDM14expressing samples were at least 50-fold greater than the lowest levels detectable by our assay (Figure 6b ). Comparisons of PRDM14 transcript levels with those of other pluripotency genes demonstrated statistically significant overexpression of POU5F1 (OCT4) in PRDM14-expressing T-ALL samples (Figure 6c ; Supplementary Figure 6 ).
Discussion
Here, we show for the first time that Prdm14 acts as a proto-oncogene in vivo. Overexpression of Prdm14 via retroviral transduction of mouse BM cells used to reconstitute lethally irradiated mice resulted in the development of LLs. Interestingly, the incidence of disease in female mice (96%) was more than twice that in male mice (42%). The onset of LL was preceded by a marked expansion of cells with the immunophenotype of CLPs. Both pre-leukemic cells and LLs from Prdm14 recipients expressed a series of pluripotency markers and oncogenes at high levels. Additionally, we detected overexpression of PRDM14 in the majority of high hyperdiploid and T-ALL samples, both in analyses of previously published array data as well as in our own analysis of primary patient samples. Significantly, little or no PRDM14 expression has been previously detected in normal mouse or human tissues other than in pluripotent cells (Nishikawa et al., 2007; Surani et al., 2007; Dettman and Justice, 2008; Tsuneyoshi et al., 2008; Yamaji et al., 2008) . Combined with our leukemogenic mouse model, our discovery of PRDM14 expression in human leukemias suggests a novel mechanism of cancer initiation and possibly tumor progression in human hematopoietic malignancies. Importantly, we have shown that a PR domaincontaining protein can initiate cancer. Usually, isoforms of genes that contain a PR domain act as tumor suppressors in vivo. Even though Prdm1 functions in a signaling cascade with Prdm14 in establishing pluripotency in PGC development (Ohinata et al., 2009) , PRDM1 functions as a tumor suppressor in diffuse large B-cell lymphomas (DLBCLs) (Pasqualucci et al., 2006) . Perhaps the differences between Prdm14 and Prdm1 in cancer are related to their normal functions in PGC development: Prdm1 represses somatic cell gene transcription in PGCs, while Prdm14 is essential for epigenetic reprogramming events required to establish the pluripotency of nascent PGCs . The high ratio of upregulated to downregulated genes in our gene expression array analyses also suggests that Prdm14 functions in transcriptional activation, unlike other PR domain-containing proteins, which primarily function as transcriptional repressors. Our expression data are consistent with expression profiles of human embryonic stem cells depleted of PRDM14 (Chia et al., 2010) .
Prdm14 acts as a proto-oncogene by interfering with normal hematopoietic development. Despite levels of engraftment similar to those of EV-transduced marrow cells at 4 weeks post reconstitution, Prdm14-expressing marrow cells contributed a smaller fraction of PB cells. By 12 weeks post reconstitution, engraftment of Prdm14-transduced cells had declined, and the contribution of Prdm14-expressing cells to T-cell, myeloid cell and erythrocytic lineages was negligible. Although these findings could suggest innately impaired engraftment potential because of Prdm14 expression, it is more likely that they simply reflect the skewed cellular differentiation that occurs in Prdm14-transduced marrow. Most significantly, marrow populations of IL-7R þ lin À early lymphoid progenitors, especially CLP-like cells, were dramatically increased at 4 weeks over baseline. By 12 weeks, the frequency of these IL-7Ra þ lin -Kit þ Sca1 þ cells started to decline. However, a concomitant expansion of B-lineage cells and developmental arrest at the pro-B-cell stage both suggest that a fraction of these cells attempted but failed to complete B-cell differentiation. Gene expression analysis of pre-leukemic cells was consistent with this block, with upregulation of genes associated with commitment to the B-lineage (Tcf3, Il7r) and downregulation of genes associated with B-cell maturation and activation (Cd27, Lat2 and Blnk). Despite waning overall engraftment of transduced cells, 80% of Prdm14 recipients eventually developed a spectrum of clonal, GFP-expressing LLs arrested at varying stages of lymphoid development including prepro-B, pro-B, precursor T and even CLP. This diversity of tumors suggests that the expansion of a hardy immature lymphoid population derived from Prdm14transduced cells led directly to the development of leukemias in these mice.
Epigenetic events that would normally lead to a pluripotent state in germ cells seem to be perturbed in cells aberrantly expressing Prdm14, resulting in expanded populations of stem-like progenitor cells. Although global epigenetic changes were not observed in Prdm14-expressing tumors (data not shown), the zinc fingers in PR domain proteins target the protein to specific DNA sequences (Chia et al., 2010; Myers et al., 2010) . Prdm14-expressing pre-leukemic cells overexpressed genes at imprinted loci, including H19, Odz4, Dlk1 and Meg3. Dlk1 and Meg3 are encoded within a complex locus, Dlk1-Dio3, which regulates the pluripotency of mouse embryonic stem cells and iPS cells (Liu et al., 2010; Stadtfeld et al., 2010) . Differentially methylated regions throughout the locus regulate reciprocal imprinting of Dlk1 and adjacent non-coding RNAs including Meg3. In human disease, abnormal methylation at DLK1 correlates with biallelic overexpression in 61% of acute myelogenous leukemias (Khoury et al., 2010) . Further, DLK1 overexpression is associated with myelodysplastic syndrome as well as megakaryocytic and erythroleukemias (Sakajiri et al., 2005) . Given that Prdm14 resets the epigenetic programming of PGCs, the overexpression of imprinted genes in our tumors indicates that genes or long noncoding RNAs within loci such as Dlk1-Dio3 may be targets of Prdm14 in resetting pluripotency. Surprisingly, Prdm14 overexpression induced upregulation of the early embryonic histone methyltransferase Glp. Glp is also upregulated in Prdm14 À/À mice, leading the authors to conclude that Prdm14 directly inhibits Glp . However, our finding may reflect a more complex regulatory scheme for expression of Glp.
On the basis of our gene expression profiling of the pre-leukemic population, Prdm14 triggered a cascade of altered gene expression induced via multiple pathways involved in oncogenesis (Figure 7a ). Upregulation of genes involved in the EMT suggests a phenotype of cancer stem cell activation, tumor invasiveness, increased metastasis and increased drug resistance (Hennessy et al., 2009; Singh and Settleman, 2010) . Selfrenewal pathways (Wnt, Ras and AKT) exhibited altered expression of pathway initiators (that is, Hhex, Tcf3) and mediators (that is, Mtor) suggestive of partial constitutive pathway activation. Notably, stem cell markers, such as Kit and Myc were overexpressed in tumors compared with normal spleen, but had the same expression levels as in BM, reflective of stem cell-like characteristics in mature tumors. These genes are associated with both PGC development and a stem cell phenotype in human leukemias and breast cancers (Besmer et al., 1993; Palmu et al., 2002; Ko et al., 2003; Tsuda et al., 2005) .
Although pre-leukemic cell populations expanded soon after transplantation, Prdm14-transduced mice exhibited an extended latent period before developing leukemia. Activation of the p53 pathway and the proapoptotic Bcl-family genes Bax and Bbc3 (PUMA) may prevent the rapid development of tumors (Figure 7a ). Unlike the pre-leukemic cells, however, mature tumors exhibited further gene expression changes that likely overwhelm normal anti-proliferative controls. Eventual overexpression of Pou5f1 and Prdm1 in mature tumors, in combination with previously expressed genes from the Dlk1-Dio3 locus, point to a powerful trend toward pluripotent drive independent of Sox2 and Nanog expression. POU5F1 overexpression in both mouse LLs and human T-ALL with PRDM14 overexpression suggests activation of pluripotency as a means of selfrenewal. Prdm14-induced LLs also expressed Myb at high levels, both as transcript and protein. Myb induces increased self-renewal of hematopoietic cells and is required for the upregulation of many lymphoidassociated genes, including Il7r, as well as for the earliest stages of lymphoid commitment in lymphoid primed progenitors (Ramsay and Gonda, 2008; Greig et al., 2010) . Given the essential role of Myb in the development of the CLP population (Greig et al., 2010) , eventual expansion of and tumor evolution from our abnormal CLP-like cells may well be triggered once Myb expression increases. MYB is also highly expressed in estrogen receptor-positive breast cancer cells, and its transcription is activated when estradiol binds estrogen receptor alpha (Guerin et al., 1990; Drabsch et al., 2007) . The linkage between estrogen and levels of Myb expression may help explain the higher frequency of Prdm14-induced LLs in female than in male mice observed in this study. Identification of cells with cancer-initiating properties has become a driving force in tumor biology. It has been hypothesized that stem cells with the ability to selfrenew, a process by which cells maintain the ability to undergo extensive proliferation while preserving the undifferentiated state, lie at the origins of all cancers with tumors developing from maturational arrest of tissue-specific stem cells. The results of this study outline a model of an ancestral, pre-leukemic clone in the mouse from a population of IL-7Ra þ lin À Kit þ Sca1 þ lymphoid progenitor cells with impaired ability to complete maturation. Evolution from an apparent ancestral clone has been demonstrated in childhood ALL in multiple analyses of paired diagnosis and relapse samples, in which tumors from a subset of patients lost some chromosomal abnormalities at relapse, while other abnormalities were retained (Davi et al., 1996; Ford et al., 2001; Mullighan et al., 2008; Davidsson et al., 2010) . We therefore propose a model for the development of PRDM14-expressing LLs: an initiating mutation in a susceptible progenitor cell perturbs its selfrenewal or differentiation to expand a pool of leukemiainitiating cells, which initially proliferate slowly (Figure 7b ). The leukemia-initiating cells attempt but fail to complete the developmental program, which then goes awry (Castor et al., 2005; Jordan, 2006; Tremblay et al., 2010) . In human disease, these persistent and abnormal leukemia-initiating cell clones could resist therapy simply because of their indolent state, with their propensity to self-renew and acquire new mutations leading to subsequent malignant retransformation and disease relapse.
Although LLs arise from an expanded progenitor pool in our mouse model of Prdm14-induced leukemogenesis, PRDM14 may be a cancer stem cell oncogene that is dependent on the cellular milieu in which it is expressed to trigger cancer. For instance, PRDM14 is overexpressed in a large proportion of human breast cancers as a result of gene amplification and in association with aberrant CpG methylation of the second intron (Hu et al., 2005; Nishikawa et al., 2007) . If PRDM14 acts similarly in breast tissue and in hematopoietic cells, it may activate a pluripotency cascade in differentiated cells that leads to the development of self-renewing, de-differentiated, pre-cancerous clones, if not a 'cancer stem cell' (Villadsen et al., 2007) . We conclude that in light of its broad relevance to cancer initiation, as well as its limited expression in normal tissues, PRDM14 and its regulatory targets are likely to provide prime candidates for therapeutic interventions in cancer.
Materials and methods
Animal care
All mouse experiments were carried out under the approval of the Institutional Animal Care and Use Committee at Baylor College of Medicine (BCM). Mice were housed in the barrier facility at BCM, under the care of the Center for Comparative Medicine, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.
Human samples
Patient samples were obtained between 1996 and 2004 through an institutional review board-approved protocol (Molecular Characterization of Normal and Abnormal Hematopoiesis, H3342) at Texas Children's Hospital (Houston, TX, USA) after informed consent was obtained. Samples from PB via venipuncture or leukopheresis, or from BM via aspiration, were lysed in Ultraspec RNA reagent (Biotecx, Houston, TX, USA) for long-term storage.
Molecular cloning of Prdm14
The coding sequence of Prdm14 was amplified using Platinum Pfx (Invitrogen, Carlsbad, CA, USA) using cDNA isolated from the ecotropic viral insertion site 32 insertion-containing tumor, 27-001, and subcloned into the MIGR1 vector, a gift from Robert Hawley (Hawley et al., 1992) using XhoI restriction enzyme sites designed in the primer sequences. The murine stem cell virus-based vector was chosen because of its known efficiency in infecting hematopoietic stem cells (Sauvageau et al., 1995; Yan et al., 1996; Persons et al., 1997) . The recombinant virus was sequenced to verify integrity and orientation.
Retroviral transductions
Retroviral supernatants were produced via transient transfection of 293T cells with the Prdm14-MIGR1 vector or a MIGR1-EV along with the PCL-Eco packaging construct using Lipofectamine 2000 (Invitrogen) (Naviaux et al., 1996) . Retrovirus-containing supernatants were collected 48 h posttransfection and were titered by infection of NIH3T3 fibroblasts followed by flow cytometric analyses to determine percentages of GFP-positive cells. Donor C57BL/6J-CD45.2 mice were injected intraperitoneally with 150 mg/kg of 5-fluorouracil. The mice were killed 6 days later, and total BM cells were isolated. Donor BM cells were incubated in Stempro 34 media (Invitrogen) containing 6 ng/ml IL-3, 10 ng/ ml IL-6, and 100 ng/ml stem cell factor (Peprotech, Rocky Hill, NJ, USA). Polybrene was added to the media at a final concentration of 4 mg/ml, and retroviral supernatants were added to the cells at a multiplicity of infection of one. Cells were spin-infected at 1266 Â g for 2 h at room temperature.
Sex-matched recipient C57BL/6J-CD45.1 mice given a split dose of 11 gray of g-irradiation were injected via the retroorbital sinus with 10 5 BM cells. Control mice were subjected to irradiation to ensure lethal levels. Irradiated mice were monitored daily for signs of morbidity.
Flow cytometry
Flow cytometry was carried out on PB and on cell suspensions prepared from tumors, BM, spleen and thymus. PB was collected from the retro-orbital sinus followed by treatment with ammonium-chloride lysing buffer to remove red blood cells. Cells were stained with cocktails of fluorescently labeled antibodies for lineage (CD45.2, B220, CD4, CD8, Mac1 and Gr1), for B-cell development (CD19, CD43, IgM and B220), for late T-cell development (CD3, CD4 and CD8), for early T-cell development (CD25, CD44, CD4 and CD8), for CLP (IL-7-Ra, Kit, Sca-1, CD4, CD8, CD3, B220, Ter119, Mac1 and Gr1) or for erythroid and natural killer cells (Ter119 and NK1.1) (BD Biosciences, San Jose, CA, USA; eBiosciences, San Diego, CA, USA). Nucleated cells were gated based on forward scatter and side scatter, with propidium iodide staining used to exclude dead cells. Cells were analyzed using a four laser BD Special Order LSR-II (BD Biosciences). FlowJo Software was used for data analyses (Tree Star Inc., Ashland, OR, USA).
Gene expression analysis
RNA was extracted, and cDNA generated, according to standard protocols (Supplementary Methods). Quantitative reverse transcription polymerase chain reaction was carried out in triplicate using the ABI Prism 7000 Sequence Detection System and ABI 7900HT Fast Real-Time PCR system (Applied Biosystems (ABI), Carlsbad, CA, USA). Gene expression studies were conducted with SybrGreen Master Mix (ABI) and custom primers ( Supplementary Table 2 ), designed using Primer Express 3.0 (ABI) and Real-Time PCR design tool (Integrated DNA Technologies, Coralville, IA, USA). Human PRDM14 expression was determined using TaqMan gene expression assay Hs01119055_m1 with Gene Expression Master Mix (ABI). PCR and fold change analysis were performed as described previously (Dettman and Justice 2008) . GAPDH and 18S ribosomal RNA served as reference genes in mouse tissue; TBP (ABI assay 4326322E) was used as the reference in human tissue (Lossos et al., 2003) .
Gene expression microarray
In all, 30 000 IL-7Ra þ lin À Kit þ Sca1 þ cells were sorted from whole BM obtained from Prdm14-transduced and EVtransduced mice 4 weeks post transplantation using BD FACSAira II (BD Biosciences), with 492% post-sort cell purity. Total RNA was obtained using RNAqueous Micro (Ambion, Austin, TX, USA). RNA quality was assessed with the Experion bioanalyzer using the Stdsens Chip (Bio-Rad, Hercules, CA, USA). RNA samples were amplified with in vitro transcription using the Illumina TotalPrep RNA Amplification kit (Ambion). RNA was then labeled and hybridized to MouseWG-6 v2.0 Expression BeadChip arrays (Illumina, San Diego, CA, USA). Data were normalized using variance-stabilizing transformation, robust spine normaliza-tion. Quality control ( Supplementary Figure 4) , hybridization and data generation were performed by the Laboratory for Translational Genomics at BCM. Data were analyzed by R (www.r-project.org) and visualized in Genespring (Agilent, Santa Clara, CA, USA). Gene ontology and pathway analysis was performed with the Database for Annotation, Visualization, and Integrated Discovery at http://david.abcc.ncifcrf.gov (Dennis et al., 2003; Huang da et al., 2009) .
Histology-pathology
Tumors were fixed using 10% aqueous buffered zinc formalin overnight at room temperature. Samples were dehydrated in ethanol and embedded in paraffin. Tumors were stained with hematoxylin and eosin (Sigma-Aldrich, St Louis, MO, USA) and analyzed according to established parameters in mouse tumor identification (Fredrickson et al., 1995; Morse et al., 2002) .
Western analysis
Western blots were performed using protein extracts from homogenized tumor cells and sorted cells, as previously described (Boles et al., 2009) . Antibodies directed against actin and Myb were obtained commercially (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis
Publicly available expression data from four pediatric ALL studies (Ross et al., 2003; Bhojwani et al., 2006; Maser et al., 2007; Sorich et al., 2008) were evaluated for PRDM14 expression levels. Outlier analysis was conducted at the 75, 90 and 95th percentiles of expression levels to evaluate for presence of a subset of tumors overexpressing PRDM14. Oncomine (Compendia Bioscience, Ann Arbor, MI, USA) was used for analysis and visualization.
Comparative analysis of gene expression fold change was performed with DataAssist v2.0 (ABI) and Prism v5.0 (GraphPad, La Jolla, CA, USA). Mann-Whitney tests were used to compare relative gene expression levels; error bars represent the median with interquartile range. Log rank analysis of overall survival was performed using Prism v5.0.
